Clinical Trial Update: A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates atezolizumab versus placebo as adjuvant therapy in high-risk muscle-invasive bladder cancer patients who are ctDNA positive after c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Muscle-invasive Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING